MENOSTAR by Bayer is characteristics. First approved in 2004.
Drug data last refreshed 4d ago
MENOSTAR is a transdermal estradiol system approved in 2004 for treating hot flashes, Turner syndrome, and osteopenia in postmenopausal women. It works by binding to estrogen receptors in target tissues to replace deficient estrogen and modulate pituitary gonadotropin secretion. Estradiol is the most potent naturally occurring estrogen and addresses the hormonal deficit following menopause.
Product approaching loss of exclusivity with minimal Part D volume ($612K, 1,572 claims in 2023); small team structure likely with defensive positioning.
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Worked on MENOSTAR at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MENOSTAR shows zero linked job openings, reflecting its mature, declining commercial status and limited career growth potential at Bayer. Professionals on this brand are managing a franchise in transition toward generic competition with shrinking headcount and reduced strategic priority.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo